NTRAHealthcare · Diagnostics & ResearchThe 23 Wall Street analysts covering Natera, Inc. hold a median 12-month price target of $459 — +5.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 28 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Natera, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Issuance (26): The company has been issuing shares or taking on financing, diluting existing holders.
Size (4): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on NTRA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +5.3% from it.
Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Oct 2026 | BTIG | Maintains | Buy | $320 → $430 |
| 19 Oct 2026 | Canaccord Genuity | Maintains | Buy | $375 → $500 |
| 14 Oct 2026 | JP Morgan | Maintains | Overweight | $360 → $460 |
| 13 Oct 2026 | Morgan Stanley | Maintains | Overweight | $355 → $435 |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $340 → $480 |
| 7 Oct 2026 | Barclays | Maintains | Overweight | $340 → $475 |
| 7 Oct 2026 | Barclays | Maintains | Overweight | — |
| 6 Oct 2026 | Citigroup | Maintains | Buy | $365 → $480 |
| 6 Oct 2026 | Citigroup | Maintains | Buy | — |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $360 → $475 |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | — |
| 25 Sept 2026 | RBC Capital | Maintains | Outperform | $350 → $460 |
| 25 Sept 2026 | RBC Capital | Maintains | Outperform | — |
| 9 Sept 2026 | UBS | Maintains | Buy | $290 → $435 |
| 9 Sept 2026 | UBS | Maintains | Buy | — |
| 8 Sept 2026 | Rothschild & Co | Initiates | Buy | $385 |
| 8 Sept 2026 | Rothschild & Co | Initiates | Buy | — |
| 13 Aug 2026 | Citigroup | Maintains | Buy | $315 → $365 |
| 13 Aug 2026 | Citigroup | Maintains | Buy | — |
| 12 Aug 2026 | Guggenheim | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NTRA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Natera, Inc. returned +126.1% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 8% of US stocks
Cheaper than 3% of US stocks
Cheaper than 98% of US stocks
Higher than 82% of US stocks
Higher than 78% of US stocks
Higher than 24% of US stocks
Higher than 22% of US stocks
Higher than 35% of US stocks
Higher than 28% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Natera, Inc. has a market value of $59.2B and an enterprise value of $57.5B.
Revenue in the twelve months to 30 June 2026: $2.7B. The latest quarter grew 37.7% year on year.
Net income over the same four quarters: −$192.3M, a −7.1% net margin.
Free cash flow in the twelve months to 30 June 2026: $51.2M.
Trailing P/E: −270.2×; forward P/E: −2310.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Natera, Inc. employs 4,424 people — $612K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Natera, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks says Natera lacks the combination of two key factors that would support a likely earnings beat in its upcoming Q3 report.
Why it matters — The item highlights expectations for Natera’s upcoming earnings release and the possibility of negative earnings.
The Parnassus Mid Cap Growth Fund said Health Care holdings were the primary driver of its outperformance in Q3, while Information Technology holdings and an underweight to Energy detracted. Year to date, the Fund returned 5.80% net of fees, versus 1.01% for the Russell Midcap Growth Index.
Why it matters — The excerpt highlights strength in the Fund’s Health Care holdings but does not identify Natera or provide NTRA-specific information.
Natera announced it will report third-quarter 2026 results after market close on November 5, 2026. The company will host a conference call and webcast at 4:30 p.m. ET that day.
Why it matters — The announcement provides NTRA watchers with the timing and access details for the company’s next quarterly results and related discussion.
Class A shares of Alger Dynamic Opportunities Fund underperformed the S&P 500 in Q3 2026. Aggregate long positions detracted from absolute and relative performance, while short positions contributed to both.
Why it matters — The excerpt provides fund-level performance information but no Natera-specific details, so it offers no direct update on NTRA.
Natera's upcoming third-quarter 2026 results are expected to hinge on Signatera volume growth, regulatory milestones and higher test prices. Expanding Medicare coverage may also support organ health revenues.
Why it matters — NTRA watchers will be looking for updates on these factors and their role in the company's results.
The 23 Wall Street analysts covering Natera, Inc. have a median 12-month price target of $459, with estimates ranging from $280 to $500. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 23 analysts covering Natera, Inc., 21 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Natera, Inc. 72 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Natera, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 23 analysts implies +5.3% from the last close, and Ticker Nerd's factor model ranks Natera, Inc. 72 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Natera, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $280 to $500 over the next 12 months.
Natera, Inc. returned +126.1% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "Natera (NTRA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release". Zacks says Natera lacks the combination of two key factors that would support a likely earnings beat in its upcoming Q3 report.
Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use. The company focuses on oncology, women’s health, and organ health, using proprietary molecular assays and bioinformatics to help detect and monitor genetic conditions and disease-related changes from small blood samples. Its current product portfolio includes prenatal screening, carrier screening, cancer monitoring, and transplant rejection assessment tests, serving physicians, hospitals, health systems, transplant centers, and biopharma partners. Natera’s tests are used to support areas such as reproductive health, cancer residual disease monitoring, recurrence surveillance, and organ transplant management. Headquartered in Austin, Texas, Natera plays an important role in the growing precision medicine market by providing non-invasive diagnostic tools that help inform clinical decision-making across multiple medical specialties.
CEO Mr. Steven Leonard Chapman · 4,424 employees · United States · https://www.natera.com
